<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04828525</url>
  </required_header>
  <id_info>
    <org_study_id>0702-20-RMC</org_study_id>
    <nct_id>NCT04828525</nct_id>
  </id_info>
  <brief_title>Corticosteroids as an Additional Treatment for Mastoiditis In Children</brief_title>
  <acronym>COSMIC</acronym>
  <official_title>Corticosteroids as an Additional Treatment for Mastoiditis In Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ori snapiri</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the influence of adjuvant corticosteroid treatment in acute&#xD;
      mastoiditis in children. we expect a better outcome in children treated with both&#xD;
      corticosteroids and antibiotics including lower rates in complications and earlier decline in&#xD;
      fever and inflammatory markers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The research is a multi-centered, prospective, placebo-control, randomized controlled trial.&#xD;
      The study group will be comprised of children diagnosed with acute mastoiditis and&#xD;
      hospitalized in a pediatric medical center.&#xD;
&#xD;
      The participating patients will be randomized divided into two groups. Research group will be&#xD;
      given dexamethasone treatment (course of 16 doses, 0.15 mg/kg/dose every 6 hours) in addition&#xD;
      to antibiotic treatment. Control group will be given 16 doses of 0.9% normal saline in&#xD;
      addition to antibiotic treatment. Management and treatment will be conducted according to&#xD;
      clinical condition and laboratory findings as for routine institution protocols. It should be&#xD;
      noted that the regular institutional management of children enrolled for the study will not&#xD;
      be changed due to our research.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The research is a multi-centered, prospective, placebo-control, randomized controlled trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>participants will be randomized divided into two groups. each group will be given dexamethasone or 0.9% normal saline. only the pharmacist will not be masked to the procedure.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time from the beginning of the treatment until clinical and laboratory findings are within normal limits</measure>
    <time_frame>during hospitalization, anticipated 1-2 weeks</time_frame>
    <description>fever, crp levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complication rates</measure>
    <time_frame>during hospitalization, anticipated 1-2 weeks</time_frame>
    <description>sinus vein thrombosis, intracranial collection or abscess, need for surgery</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>anticipated 1-2 weeks</time_frame>
    <description>time from admission until discharge</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Mastoiditis; Acute</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>participants will be given corticosteroids in addition to conventional treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>participants will be given normal saline in addition to conventional treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>adjuvant dexamethasone treatment</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  acute mastoiditis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  immunodeficiency (congenital or acquired)&#xD;
&#xD;
          -  significant chronic disease&#xD;
&#xD;
          -  hypertension&#xD;
&#xD;
          -  recurrent mastoiditis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ori Snapiri, Dr</last_name>
    <phone>+972547242654</phone>
    <email>orisnapiri@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chen Rosenberg Danziger, Dr</last_name>
    <phone>+972-3-925 3775</phone>
    <email>chen.danziger@gmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Lin HW, Shargorodsky J, Gopen Q. Clinical strategies for the management of acute mastoiditis in the pediatric population. Clin Pediatr (Phila). 2010 Feb;49(2):110-5. doi: 10.1177/0009922809344349. Epub 2009 Sep 4. Review.</citation>
    <PMID>19734439</PMID>
  </reference>
  <reference>
    <citation>Groth A, Enoksson F, Hultcrantz M, Stalfors J, Stenfeldt K, Hermansson A. Acute mastoiditis in children aged 0-16 years--a national study of 678 cases in Sweden comparing different age groups. Int J Pediatr Otorhinolaryngol. 2012 Oct;76(10):1494-500. doi: 10.1016/j.ijporl.2012.07.002. Epub 2012 Jul 23.</citation>
    <PMID>22832239</PMID>
  </reference>
  <reference>
    <citation>Delgado-Noguera MF, Forero Delgadillo JM, Franco AA, Vazquez JC, Calvache JA. Corticosteroids for septic arthritis in children. Cochrane Database Syst Rev. 2018 Nov 21;11:CD012125. doi: 10.1002/14651858.CD012125.pub2.</citation>
    <PMID>30480764</PMID>
  </reference>
  <reference>
    <citation>Aljebab F, Choonara I, Conroy S. Systematic review of the toxicity of short-course oral corticosteroids in children. Arch Dis Child. 2016 Apr;101(4):365-70. doi: 10.1136/archdischild-2015-309522. Epub 2016 Jan 14. Review.</citation>
    <PMID>26768830</PMID>
  </reference>
  <reference>
    <citation>Brouwer MC, McIntyre P, Prasad K, van de Beek D. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev. 2015 Sep 12;(9):CD004405. doi: 10.1002/14651858.CD004405.pub5. Review.</citation>
    <PMID>26362566</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 30, 2021</study_first_submitted>
  <study_first_submitted_qc>March 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2021</study_first_posted>
  <last_update_submitted>April 4, 2021</last_update_submitted>
  <last_update_submitted_qc>April 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rabin Medical Center</investigator_affiliation>
    <investigator_full_name>ori snapiri</investigator_full_name>
    <investigator_title>Pediatrician, Principal Investigator, Clinical doctor</investigator_title>
  </responsible_party>
  <keyword>mastoiditis</keyword>
  <keyword>children</keyword>
  <keyword>corticosteroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mastoiditis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

